Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000597745 | SCV000700344 | pathogenic | not provided | 2017-03-09 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001860148 | SCV002124520 | pathogenic | Fabry disease | 2021-12-18 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. This variant disrupts the p.Ser148 amino acid residue in GLA. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 10666480, 19387866, 21598360). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. Experimental studies have shown that this missense change affects GLA function (PMID: 18205205, 21598360). Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Tolerated"; PolyPhen-2: "Probably Damaging"; Align-GVGD: "Class C0"). ClinVar contains an entry for this variant (Variation ID: 496827). This missense change has been observed in individual(s) with Fabry disease (PMID: 15091117, 18205205). This variant is not present in population databases (gnomAD no frequency). This sequence change replaces serine, which is neutral and polar, with asparagine, which is neutral and polar, at codon 148 of the GLA protein (p.Ser148Asn). |